Cargando…

Early Findings after Implementation of Veno-Arteriovenous ECMO: A Multicenter European Experience

Extracorporeal membrane oxygenation (ECMO) is increasingly used to treat cardiopulmonary failure in critically ill patients. Peripheral cannulation may be complicated by a persistent low cardiac output in case of veno-venous cannulation (VV-ECMO) or by differential hypoxia (e.g., lower PaO(2) in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Blandino Ortiz, Aaron, Belliato, Mirko, Broman, Lars Mikael, Lheureux, Olivier, Malfertheiner, Maximilian Valentin, Xini, Angela, Pappalardo, Federico, Taccone, Fabio Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912524/
https://www.ncbi.nlm.nih.gov/pubmed/33499236
http://dx.doi.org/10.3390/membranes11020081
_version_ 1783656596419641344
author Blandino Ortiz, Aaron
Belliato, Mirko
Broman, Lars Mikael
Lheureux, Olivier
Malfertheiner, Maximilian Valentin
Xini, Angela
Pappalardo, Federico
Taccone, Fabio Silvio
author_facet Blandino Ortiz, Aaron
Belliato, Mirko
Broman, Lars Mikael
Lheureux, Olivier
Malfertheiner, Maximilian Valentin
Xini, Angela
Pappalardo, Federico
Taccone, Fabio Silvio
author_sort Blandino Ortiz, Aaron
collection PubMed
description Extracorporeal membrane oxygenation (ECMO) is increasingly used to treat cardiopulmonary failure in critically ill patients. Peripheral cannulation may be complicated by a persistent low cardiac output in case of veno-venous cannulation (VV-ECMO) or by differential hypoxia (e.g., lower PaO(2) in the upper than in the lower body) in case of veno-arterial cannulation (VA-ECMO) and severe impairment of pulmonary function associated with cardiac recovery. The treatment of such complications remains challenging. We report the early effects of the use of veno-arterial-venous (V-AV) ECMO in this setting. Methods: Retrospective analysis including patients from five different European ECMO centers (January 2013 to December 2016) who required V-AV ECMO. We collected demographic data as well as comorbidities and ECMO characteristics, hemodynamics, and arterial blood gas values before and immediately after (i.e., within 2 h) V-AV implementation. Results: A total of 32 patients (age 53 (interquartiles, IQRs: 31–59) years) were identified: 16 were initially supported with VA-ECMO and 16 with VV-ECMO. The median time to V-AV conversion was 2 (1–5) days. After V-AV implantation, heart rate and norepinephrine dose significantly decreased, while PaO(2) and SaO(2) significantly increased compared to baseline values. Lactate levels significantly decreased from 3.9 (2.3–7.1) to 2.8 (1.4–4.4) mmol/L (p = 0.048). A significant increase in the overall ECMO blood flow (from 4.5 (3.8–5.0) to 4.9 (4.3–5.9) L/min; p < 0.01) was observed, with 3.0 (2.5–3.2) L/min for the arterial and 2.8 (2.1–3.6) L/min for the venous return flows. Conclusions: In ECMO patients with differential hypoxia or persistently low cardiac output syndrome, V-AV conversion was associated with improvement in some hemodynamic and respiratory parameters. A significant increase in the overall ECMO blood flow was also observed, with similar flow distributed into the arterial and venous return cannulas.
format Online
Article
Text
id pubmed-7912524
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79125242021-02-28 Early Findings after Implementation of Veno-Arteriovenous ECMO: A Multicenter European Experience Blandino Ortiz, Aaron Belliato, Mirko Broman, Lars Mikael Lheureux, Olivier Malfertheiner, Maximilian Valentin Xini, Angela Pappalardo, Federico Taccone, Fabio Silvio Membranes (Basel) Article Extracorporeal membrane oxygenation (ECMO) is increasingly used to treat cardiopulmonary failure in critically ill patients. Peripheral cannulation may be complicated by a persistent low cardiac output in case of veno-venous cannulation (VV-ECMO) or by differential hypoxia (e.g., lower PaO(2) in the upper than in the lower body) in case of veno-arterial cannulation (VA-ECMO) and severe impairment of pulmonary function associated with cardiac recovery. The treatment of such complications remains challenging. We report the early effects of the use of veno-arterial-venous (V-AV) ECMO in this setting. Methods: Retrospective analysis including patients from five different European ECMO centers (January 2013 to December 2016) who required V-AV ECMO. We collected demographic data as well as comorbidities and ECMO characteristics, hemodynamics, and arterial blood gas values before and immediately after (i.e., within 2 h) V-AV implementation. Results: A total of 32 patients (age 53 (interquartiles, IQRs: 31–59) years) were identified: 16 were initially supported with VA-ECMO and 16 with VV-ECMO. The median time to V-AV conversion was 2 (1–5) days. After V-AV implantation, heart rate and norepinephrine dose significantly decreased, while PaO(2) and SaO(2) significantly increased compared to baseline values. Lactate levels significantly decreased from 3.9 (2.3–7.1) to 2.8 (1.4–4.4) mmol/L (p = 0.048). A significant increase in the overall ECMO blood flow (from 4.5 (3.8–5.0) to 4.9 (4.3–5.9) L/min; p < 0.01) was observed, with 3.0 (2.5–3.2) L/min for the arterial and 2.8 (2.1–3.6) L/min for the venous return flows. Conclusions: In ECMO patients with differential hypoxia or persistently low cardiac output syndrome, V-AV conversion was associated with improvement in some hemodynamic and respiratory parameters. A significant increase in the overall ECMO blood flow was also observed, with similar flow distributed into the arterial and venous return cannulas. MDPI 2021-01-22 /pmc/articles/PMC7912524/ /pubmed/33499236 http://dx.doi.org/10.3390/membranes11020081 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Blandino Ortiz, Aaron
Belliato, Mirko
Broman, Lars Mikael
Lheureux, Olivier
Malfertheiner, Maximilian Valentin
Xini, Angela
Pappalardo, Federico
Taccone, Fabio Silvio
Early Findings after Implementation of Veno-Arteriovenous ECMO: A Multicenter European Experience
title Early Findings after Implementation of Veno-Arteriovenous ECMO: A Multicenter European Experience
title_full Early Findings after Implementation of Veno-Arteriovenous ECMO: A Multicenter European Experience
title_fullStr Early Findings after Implementation of Veno-Arteriovenous ECMO: A Multicenter European Experience
title_full_unstemmed Early Findings after Implementation of Veno-Arteriovenous ECMO: A Multicenter European Experience
title_short Early Findings after Implementation of Veno-Arteriovenous ECMO: A Multicenter European Experience
title_sort early findings after implementation of veno-arteriovenous ecmo: a multicenter european experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912524/
https://www.ncbi.nlm.nih.gov/pubmed/33499236
http://dx.doi.org/10.3390/membranes11020081
work_keys_str_mv AT blandinoortizaaron earlyfindingsafterimplementationofvenoarteriovenousecmoamulticentereuropeanexperience
AT belliatomirko earlyfindingsafterimplementationofvenoarteriovenousecmoamulticentereuropeanexperience
AT bromanlarsmikael earlyfindingsafterimplementationofvenoarteriovenousecmoamulticentereuropeanexperience
AT lheureuxolivier earlyfindingsafterimplementationofvenoarteriovenousecmoamulticentereuropeanexperience
AT malfertheinermaximilianvalentin earlyfindingsafterimplementationofvenoarteriovenousecmoamulticentereuropeanexperience
AT xiniangela earlyfindingsafterimplementationofvenoarteriovenousecmoamulticentereuropeanexperience
AT pappalardofederico earlyfindingsafterimplementationofvenoarteriovenousecmoamulticentereuropeanexperience
AT tacconefabiosilvio earlyfindingsafterimplementationofvenoarteriovenousecmoamulticentereuropeanexperience